Wegovy prescriptions in US drop in first this year, increase in Denmark

Novo Nordisk is still challenged on making enough of the popular obesity treatment to supply the US market.
Photo: Jim Vondruska/Reuters/Ritzau Scanpix
Photo: Jim Vondruska/Reuters/Ritzau Scanpix
by marketwire & ritzau, translated by daniel pedersen

Danish drugmaker Novo Nordisk’s challenges with producing enough of its popular obesity treatment, Wegovy, for the US market can now be seen in the country’s prescription figures.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading